Related Experiment Videos
Prognostic factors for medulloblastoma
D Jenkin1, M A Shabanah, E A Shail
1Department of Oncology, King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia.
Summary
Medulloblastoma stage M0+M1 is the strongest predictor of survival. Advanced disease at diagnosis significantly impacts outcomes, highlighting the need for tailored treatment strategies in Saudi Arabia.
Area of Science:
- Pediatric Oncology
- Neuro-Oncology
- Cancer Prognostics
Background:
- Medulloblastoma is a common malignant brain tumor in children.
- Prognostic factors are crucial for tailoring treatment and predicting outcomes.
Purpose of the Study:
- To identify and evaluate prognostic factors for medulloblastoma patients.
- To assess the impact of disease stage on survival rates.
Main Methods:
- Retrospective review of 173 medulloblastoma patients treated between 1988-1997.
- Analysis of treatment protocols, including surgical intent, radiation, and chemotherapy.
- Evaluation of prognostic indicators such as age, tumor stage, and tumor characteristics.
Main Results:
- Five-year survival was 58% for patients completing treatment, versus 0% for those who did not.
- Stage M0+M1 (localized disease) had a 78% survival rate, while M2+M3 (disseminated disease) had a 21% survival rate (p < 0.0001).
- Favorable factors included age >14 years and gross cystic/necrotic features; tumor size and hydrocephalus were not significant.
Conclusions:
- Disease stage (M0+M1) is the most powerful prognostic factor for medulloblastoma.
- Higher incidence of advanced disease in Saudi Arabia negatively affects survival.
- Standard resection and radiation were less sensitive prognostic indicators in this cohort due to high adherence to treatment protocols.